Low-priced oncology disruptors: The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Novel oncologic drugs continue to command premium pricing, driven by a combination of unmet needs, and delivering often-iterative, sometimes-significant...
Justus Dehnen is a vice president in the Life Sciences Practice with more than 20 years in the industry.
His consulting experience focuses on pricing and market access, contracting and loss of exclusivity (LoE) strategy development projects for national and international Life Science companies. He works across multiple therapeutic areas for pharma, biotech, and medical device companies. Mr. Dehnen has helped life science companies to develop and maintain access, pricing, and reimbursement along the product lifecycle from early pipeline to LoE.
Prior to his role at CRA, Mr. Dehnen was a Principal at QuintilesIMS Consulting Group where he was a member of the global Pricing and Market Access leadership team and head of the Munich office. Previously, he served as CEO of Genmedics Biotechnology GmbH and was a senior manager at Cell Consulting AG. Before that he was a member of the Life Science Practice at Capgemini in Paris.
He is fluent in German, English, and French.